The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia
Open accessAbstract
BACKGROUND: The rate of anal cancer is increasing among both women and men, particularly men who have sex with men. Caused by infection with human papillomavirus (HPV), primarily HPV type 16 or 18, anal cancer is preceded by high-grade anal intraepithelial neoplasia (grade 2 or 3). We studied the safety and efficacy of quadrivalent HPV vaccine (qHPV) against anal intraepithelial neoplasia associated with HPV-6, 11, 16, or 18 infection in men who have sex with men. METHODS: In a substudy of a larger double-blind study, we randomly assigned 602 healthy men who have sex with men, 16 to 26 years of age, to receive either qHPV or placebo. The primary efficacy objective was prevention of anal intraepithelial neoplasia or anal cancer related to infection with HPV-6, 11, 16, or 18. Efficacy analyses were performed in intention-to-treat and per-protocol efficacy populations. The rates of adverse events were documented. RESULTS: Efficacy of the qHPV vaccine against anal intraepithelial neoplasia associated with HPV-6, 11, 16, or 18 was 50.3% (95% confidence interval [CI], 25.7 to 67.2) in the intention-to-treat population and 77.5% (95% CI, 39.6 to 93.3) in the per-protocol efficacy population; the corresponding efficacies against anal intraepithelial neoplasia associated with HPV of any type were 25.7% (95% CI, -1.1 to 45.6) and 54.9% (95% CI, 8.4 to 79.1), respectively. Rates of anal intraepithelial neoplasia per 100 person-years were 17.5 in the placebo group and 13.0 in the vaccine group in the intention-to-treat population and 8.9 in the placebo group and 4.0 in the vaccine group in the per-protocol efficacy population. The rate of grade 2 or 3 anal intraepithelial neoplasia related to infection with HPV-6, 11, 16, or 18 was reduced by 54.2% (95% CI, 18.0 to 75.3) in the intention-to-treat population and by 74.9% (95% CI, 8.8 to 95.4) in the per-protocol efficacy population. The corresponding risks of persistent anal infection with HPV-6, 11, 16, or 18 were reduced by 59.4% (95% CI, 43.0 to 71.4) and 94.9% (95% CI, 80.4 to 99.4), respectively. No vaccine-related serious adverse events were reported. CONCLUSIONS: Use of the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, among men who have sex with men. The vaccine had a favorable safety profile and may help to reduce the risk of anal cancer. (Funded by Merck and the National Institutes of Health; ClinicalTrials.gov number, NCT00090285.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa061741 · Cited by 2,055
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Self-citationVilla, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
Self-citationEfficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
Giuliano, A. R., Palefsky, J. M., Goldstone, S., Moreira, E. D., Penny, M. E., Aranda, C., Vardas, E., Moi, H., Jessen, H., Hillman, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0909537 · Cited by 1,146
Self-citationJohnson, L. G., Madeleine, M. M., Newcomer, L. M., Schwartz, S. M., & Daling, J. R. (2004) · Cancer · doi:10.1002/cncr.20364 · Cited by 641
Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions
Hoots, B. E., Palefsky, J. M., Pimenta, J. M., & Smith, J. S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24215 · Cited by 461
Self-citationPathela, P., Hajat, A., Schillinger, J., Blank, S., Sell, R., & Mostashari, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-6-200609190-00005 · Cited by 352
Piketty, C., Darragh, T. M., Costa, M. D., Bruneval, P., Heard, I., Kazatchkine, M. D., & Palefsky, J. M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-6-200303180-00008 · Cited by 300
Self-citationEvaluation of Genital Sites and Sampling Techniques for Detection of Human Papillomavirus DNA in Men
Weaver, B. A., Feng, Q., Holmes, K. K., Kiviat, N., Lee, S., Meyer, C., Stern, M., & Koutsky, L. A. (2004) · The Journal of Infectious Diseases · doi:10.1086/381395 · Cited by 253
Malignant transformation of high-grade anal intraepithelial neoplasia
Scholefield, J. H., Castle, M. T., & Watson, N. F. S. (2005) · British Journal of Surgery · doi:10.1002/bjs.4994 · Cited by 247
Cited by
Human papillomavirus and cervical cancer
Burd, E. M. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.1-17.2003 · Cited by 2,420
Sexually Transmitted Diseases Treatment Guidelines, 2010
(2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,076
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
Self-citationHuman papillomavirus and cervical cancer
Crosbie, E. J., Einstein, M. H., Franceschi, S., & Kitchener, H. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60022-7 · Cited by 1,171
Prevalence of Oral HPV Infection in the United States, 2009-2010
Gillison, M. L., Broutian, T., Pickard, R. K. L., Tong, Z.-Y., Xiao, W., Kahle, L., Graubard, B. I., & Chaturvedi, A. K. (2012) · JAMA · doi:10.1001/jama.2012.101 · Cited by 1,064
Carcinogenic human papillomavirus infection
Schiffman, M., Doorbar, J., Wentzensen, N., de Sanjosé, S., Fakhry, C., Monk, B. J., Stanley, M. A., & Franceschi, S. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.86 · Cited by 999
Machalek, D. A., Poynten, M., Jin, F., Fairley, C. K., Farnsworth, A., Garland, S. M., Hillman, R. J., Petoumenos, K., Roberts, J., Tabrizi, S. N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70080-3 · Cited by 963
Self-citationUS Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines
Saraiya, M., Unger, E. R., Thompson, T. D., Lynch, C. F., Hernandez, B. Y., Lyu, C. W., Steinau, M., Watson, M., Wilkinson, E. J., Hopenhayn, C., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv086 · Cited by 761
A review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747
Arbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009069.pub3 · Cited by 621
Cancer prevention from the perspective of global cancer burden patterns
Nagai, H., & Kim, Y. H. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.02.75 · Cited by 621
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
Palefsky, J. M., Lee, J. Y., Jay, N., Goldstone, S. E., Darragh, T. M., Dunlevy, H. A., Rosa-Cunha, I., Arons, A., Pugliese, J. C., Vena, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201048 · Cited by 512
Self-citationAnal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2014.07.030 · Cited by 481
Quinn, G. P., Sanchez, J. A., Sutton, S. K., Vadaparampil, S. T., Nguyen, G. T., Green, B. L., Kanetsky, P. A., & Schabath, M. B. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21288 · Cited by 479
Herrero, R., Quint, W., Hildesheim, A., Gonzalez, P., Struijk, L., Katki, H. A., Porras, C., Schiffman, M., Rodriguez, A. C., Solomon, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068329 · Cited by 473
Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches
Apalla, Z., Nashan, D., Weller, R. B., & Castellsagué, X. (2017) · Dermatology and Therapy · doi:10.1007/s13555-016-0165-y · Cited by 465
Herfs, M., Yamamoto, Y., Laury, A., Wang, X., Nucci, M. R., McLaughlin-Drubin, M. E., Münger, K., Feldman, S., McKeon, F. D., Xian, W., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202684109 · Cited by 437
Human Papillomavirus Vaccine Introduction – The First Five Years
Markowitz, L. E., Tsu, V., Deeks, S. L., Cubie, H., Wang, S. A., Vicari, A. S., & Brotherton, J. M. L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.039 · Cited by 364
Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu159 · Cited by 355
International trends in anal cancer incidence rates
Islami, F., Ferlay, J., Lortet-Tieulent, J., Bray, F., & Jemal, A. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw276 · Cited by 329
Human Papillomavirus Vaccines: An Updated Review
Cheng, L., Wang, Y., & Du, J. (2020) · Vaccines · doi:10.3390/vaccines8030391 · Cited by 329
Joura, E. A., Garland, S. M., Paavonen, J., Ferris, D. G., Perez, G., Ault, K. A., Huh, W. K., Sings, H. L., James, M. K., Haupt, R. M., et al. (2012) · BMJ · doi:10.1136/bmj.e1401 · Cited by 316
Self-citationUnderstanding and learning from the success of prophylactic human papillomavirus vaccines
Schiller, J. T., & Lowy, D. R. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2872 · Cited by 293
Epidemiology and Clinical Aspects of HPV in Head and Neck Cancers
Chaturvedi, A. K. (2012) · Head and Neck Pathology · doi:10.1007/s12105-012-0377-0 · Cited by 274
Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.04.013 · Cited by 269
Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer
Kamolratanakul, S., & Pitisuttithum, P. (2021) · Vaccines · doi:10.3390/vaccines9121413 · Cited by 263
Tong, W. W. Y., Jin, F., McHugh, L. C., Maher, T., Sinclair, B., Grulich, A. E., Hillman, R. J., & Carr, A. (2013) · AIDS · doi:10.1097/qad.0b013e3283633111 · Cited by 112
Self-citationCanfell, K., Kim, J. J., Kulasingam, S., Berkhof, J., Barnabas, R., Bogaards, J. A., Campos, N., Jennett, C., Sharma, M., Simms, K. T., et al. (2019) · Papillomavirus Research · doi:10.1016/j.pvr.2019.100184 · Cited by 68
Machalek, D. A., Grulich, A. E., Jin, F., Templeton, D. J., & Poynten, I. M. (2012) · Sexual Health · doi:10.1071/sh12043 · Cited by 59
Metadata
- Authors
- Palefsky, J. M., Giuliano, A. R., Goldstone, S., Moreira, E. D., Aranda, C., Jessen, H., Hillman, R., Ferris, D., Coutlee, F., Stoler, M. H., Marshall, J. B., Radley, D., Vuocolo, S., Haupt, R. M., Guris, D., & Garner, E. I. O.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-10-27
- Volume
- 365
- Issue
- 17
- Pages
- 1576-1585
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1965416300
- Cited by
- 948
- References
- 19
- FWCI
- 52.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.